March 24th 2021
By Tony Hagen
Biosimilars get short shrift in a proposed pricing model developed by the Drug Pricing Lab at Memorial Sloan Kettering (MSK), experts say.
March 23rd 2021
By Deana Ferreri, PhD
Animal toxicology studies contribute little to demonstrations of biosimilarity and yet these studies frequently must be done to satisfy international regulatory requirements, investigators conclude.
March 22nd 2021
Peter Bach, MD, MAPP, and his Drug Pricing Lab at Memorial Sloan Kettering (MSK) argue profit caps will do better than the current biosimilar system.
March 19th 2021
Following lackluster experience with biosimilar marketing in the United States, Merck moves forward with spinoff plan.
March 17th 2021
State Senator Carla Nelson explains how the pharmaceutical industry is reacting to her bill requiring payers to cover all approved biosimilars and reference products.
Pfizer said it has made a business decision to cease production of biosimilars at a $350 million plant it built recently in Hangzhou, China.
March 16th 2021
"Shocked" by the threat of competition, originator manufacturers start raising prices long before rival products appear on the scene, investigators found.
March 15th 2021
Alvotech closes on $35 million in funding, and Samsung Bioepis gets closer to marketing an adalimumab biosimilar. Alvotech's planned high-tech expansion is pictured.
March 14th 2021
State Representative Jennifer Schultz (D, Duluth) explains how her bill requiring payers to cover all approved biosimilars and reference products would save money and improve access.
March 13th 2021
The Senate has passed a bill requiring the FDA to provide educational information that supports and promotes the adoption of biosimilars.
